

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

The logo for EuroEyes, featuring the word "EuroEyes" in white sans-serif font on a dark blue rectangular background.

## **EuroEyes International Eye Clinic Limited**

**德視佳國際眼科有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1846)**

### **POSITIVE PROFIT ALERT**

This announcement is made by EuroEyes International Eye Clinic Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 (the “**Interim Period**”) and other information currently available to the Board, the Group expects to record a profit attributable to owners of the Company in the range of HK\$66 million to HK\$70 million as compared to that of the corresponding period in 2022, a profit attributable to owners of the Company in the amount of approximately HK\$46.5 million, representing an increase of approximately 42%.

Based on the currently available information, the expected increase was mainly attributable to (i) a robust growth in lens exchange surgeries in Germany, the PRC and Denmark for the treatment of Presbyopia; (ii) a significant increase in the number of eye surgeries performed by the Group in both the PRC and Denmark following the removal of restrictions associated with the COVID-19 pandemic; and (iii) several effective temporary pricing strategies were implemented in Germany to restore the demand for refractive laser surgery among young patients.

The Company is still in the process of finalising the consolidated financial results for the Interim Period. The information contained in this announcement is only a preliminary assessment by the Board based on the information currently available and the unaudited consolidated management accounts of the Group for the Interim Period, which have not been audited or reviewed by the Company’s independent auditor and/or the audit committee of the Board. The actual results of the Group for the Interim Period may be different from what is disclosed in this announcement.

Shareholders and potential investors are advised to read carefully the announcement of the interim results of the Group for the Interim Period, which is expected to be published by the end of August 2023.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**EuroEyes International Eye Clinic Limited**  
**Dr. Jørn Slot Jørgensen**  
*Chairman and Executive Director*

Hong Kong, 14 August 2023

*As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Mr. Jannik Jonas Slot Jørgensen and Professor Dan Zoltan Reinstein as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.*